Oncology Brothers: Practice-Changing Cancer Discussions

On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs. Rahul & Rohit Gosain interview world-renowned hematologists/oncologists to present the practice-changing data in a small bite-sized format where one could immediately apply that information in their daily practice to provide the best cancer care to their patients close to home.Privacy Policy: https://oncbrothers.com/privacy-policyTerms & Conditions: https://oncbrothers.com/terms-and-conditions

Oncology Brothers: Practice-Changing Cancer Discussions is a health podcast hosted by Oncology Brothers, with 279 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Oncology Brothers hosts Oncology Brothers: Practice-Changing Cancer Discussions, a health show with 279 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  SURPASS-ET: FDA Approval of Ropeginterferon alfa-2b in Essential Thrombocythemia (ET)

  Sep 14, 202623 min

  Welcome to the Oncology Brothers podcast! In this episode, we talked about the most recent developments in the world of myeloproliferative neoplasms (MPNs), including the exciting FDA approvals of ropeginterferon alfa-2b for essential thrombocythemia (ET) and rusfertide for polycythemia vera (PV). The leading author Dr. John Mascarenhas, an MPN specialist from the Mount Sinai, New York, shared insights from the SURPASS-ET study , which paved the way for the official approval of ropeginterferon alfa-2b in ET. Dr. Mascarenhas discussed the study design, findings, and the implications of using ropeginterferon alfa-2b compared to traditional therapies like anagrelide and hydroxyurea . Key topics covered in this episode included: Overview of the SURPASS-ET study and its significance Efficacy and tolerability of ropeginterferon alfa-2b in ET Side effect profiles of ropeginterferon alfa-2b vs anagrelide The importance of monitoring JAK2 allele burden and its clinical relevance Considerations for using ropeginterferon alfa-2b in frontline therapy for select patients Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore the evolving landscape of MPN treatment and the potential for disease modification with ropeginterferon alfa-2b. Don't forget to like, subscribe, and check out our other discussions on oncology topics! #EssentialThrombocythemia, #MPN, #Ropeginterferon, #SURPASSET, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann

  Sep 7, 202624 min

  Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute. Join us as we explored: The critical distinction between primary and secondary myelofibrosis and its implications for treatment The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept The role of JAK inhibitors in treatment, including ruxolitinib , momelotinib , pacritinib , and fedratinib , and how to choose among them based on patient needs The importance of spleen reduction and its correlation with patient outcomes and survival Insights into the side effect profiles of various treatments and the future of myelofibrosis management Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Managing Toxicities of Therapies in Polycythemia Vera (PV) / Essential Thrombocythemia (ET)

  Sep 4, 202627 min

  Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET). We dived deep into the side effect profiles and management strategies for key treatments, including: Hydroxyurea : Learnt about dosing strategies, monitoring, and the importance of managing acute and chronic side effects such as leg ulcers and skin cancer risks Ropeginterferon alfa-2b : Discover the benefits and potential side effects, including flu-like symptoms and neuropsychiatric issues, and how to approach dosing for patients with pre-existing conditions Ruxolitinib : Understand the common side effects, including myelosuppression and weight gain, and the critical importance of tapering off the medication rather than stopping abruptly Rusfertide : Get insights into this new hepcidin mimetic and its promising role in managing PV, along with potential side effects to monitor Join us for a comprehensive tox check discussion that aims to equip healthcare professionals with clinical pearls for managing these treatments effectively. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Subscribe for more insights and updates from the Oncology Brothers! #PolycythemiaVera, #MPN, #EssentialThrombocythemia, #CytotoxicTherapies, #OncologyBrothers

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  VERIFY: FDA Approval of Rusfertide in Polycythemia Vera (PV) - Dr. Andrew Kuykendall

  Sep 2, 202620 min

  Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study . We were joined by Dr. Andrew Kuykendall , an MPN specialist from the Moffitt Cancer Center, who shared insights on the drug's mechanism of action as a hepcidin mimetic and its clinical implications. Key topics discussed included: The unique challenges of managing polycythemia vera, with balancing of erythrocytosis and iron deficiency The design and findings of the VERIFY study, highlighting the significant reduction in the need for phlebotomy among patients treated with rusfertide The potential for individualized patient care and the integration of rusfertide with existing cytoreductive therapies Insights into dosing, side effects, and the drug's impact on patient quality of life Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we explore how rusfertide can change the treatment landscape for polycythemia vera and improve patient outcomes. Don't forget to like, subscribe, and hit the notification bell for more episodes! #Rusfertide, #PolycythemiaVera, #VERIFYstudy, #MPN, #Hematology

  ListenShow Notes
• 

  Oncology Brothers: Practice-Changing Cancer Discussions

  Polycythemia vera (PV) and Essential thrombocythemia (ET) Treatment Algorithm: Dr. Aaron Gerds

  Aug 31, 202629 min

  Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polycythemia vera (PV) and essential thrombocythemia (ET). Join us as we delved into: The diagnostic criteria for PV and ET, including the significance of JAK2 mutations and erythropoietin (EPO) levels The role of bone marrow biopsies in diagnosing and managing these conditions Treatment options for PV, including hydroxyurea , ropeginterferon alfa-2b , and ruxolitinib , as well as the approval of rusfertide The importance of risk stratification based on patient age and history of thrombosis The management of side effects associated with various treatment options The clinical utility of monitoring JAK2 allele burden and its implications for patient management Insights into the treatment landscape for ET, including the use of antiplatelet therapy and the role of acquired Von Willebrand disease Whether you're a healthcare professional or someone interested in the latest advancements in oncology, this episode provides valuable insights into the complexities of managing PV and ET. Listen us on: Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: ⁠X/Twitter: https://x.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest in hematological and oncological care! #PolycythemiaVera, #EssentialThrombocythemia, #MPN, #JAK2, #OncologyBrothers

  ListenShow Notes

Recent guests on Oncology Brothers: Practice-Changing Cancer Discussions. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.